Oncimmune (LON:ONC) Announces Quarterly Earnings Results

Oncimmune (LON:ONC) posted its quarterly earnings results on Monday. The company reported GBX (4.72) (($0.06)) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Oncimmune had a negative return on equity of 760.96% and a net margin of 586.08%.

Oncimmune Stock Performance

Shares of LON ONC opened at GBX 7.90 ($0.10) on Wednesday. Oncimmune has a one year low of GBX 7.50 ($0.09) and a one year high of GBX 31 ($0.39). The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 806.85. The business has a fifty day simple moving average of GBX 13.37 and a 200 day simple moving average of GBX 14.80. The firm has a market capitalization of £5.86 million, a price-to-earnings ratio of -263.33 and a beta of 1.19.

About Oncimmune

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.